Search

everythinglearnresearchcommunity

for

Search:↓

Aminexil, nanoxidil, stemoxydine, and kopexil are discussed as alternatives to minoxidil for hair growth, with concerns about dependence. Minoxidil is noted for its effectiveness in transitioning hair growth phases, but dependence is mainly linked to androgenic alopecia.

Poor sleep quality may affect hair growth cycles by disrupting the body's natural clock and stress hormones. The focus should be on improving sleep to support overall health, including hair growth, rather than relying solely on treatments like Minoxidil, finasteride, or RU58841.

The conversation discusses the effectiveness and side effects of taking 1.25mg oral minoxidil for hair loss, with some users suggesting starting at a lower dose to minimize side effects before potentially increasing to 2.5mg. Concerns about cardiovascular side effects and the importance of individual responses to dosage are highlighted.

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

A 31-year-old is happy with hair regrowth and thickening after using 0.5 mg dutasteride daily and 5% topical minoxidil. Initial results appeared in six months, with continued improvement over time.

A 23-year-old experienced hair regrowth using 1mg finasteride and 5mg oral minoxidil after initial shedding, but noticed hair loss after stopping minoxidil and starting vaping. They resumed oral minoxidil and finasteride, attributing hair loss to nicotine and stopping minoxidil, and are considering additional treatments like dutasteride.

The user treats hair loss with dutasteride, minoxidil, and tretinoin for about £280 a year by using dutasteride weekly due to its long half-life, while using minoxidil daily. Concerns about the shelf life and absorption of topical treatments were discussed, with some users suggesting alternative sources for these products.

Creatine is believed by some to cause hair loss, potentially by increasing DHT levels, despite conflicting evidence. Users report mixed results when combining creatine with treatments like finasteride, dutasteride, and minoxidil.

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

The user has been taking 1 mg of finasteride and 6 drops of minoxidil orally per day for five months, experiencing increased hair shedding but also noticing denser and fuller hair according to friends. Despite the shedding, the user is happy with the progress and has not experienced significant side effects, though they caution against the risks of taking minoxidil orally.

Oleic acid, microneedling, and emu oil are discussed as potential hair growth treatments, with some users expressing skepticism about their effectiveness. Minoxidil and finasteride are recommended as current reliable treatments until more proven solutions are available.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

A 24-year-old male experienced side effects like low libido and ED after starting finasteride post-hair transplant and is seeking alternatives to reduce scalp DHT. Suggestions include topical finasteride, Xpecia, DHT-reducing shampoos, and switching to dutasteride, with some users reporting fewer side effects with these alternatives.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

Scientists claim a combination of caffeine, two proteins, and Centella asiatica extracts can cure hair loss, but skepticism remains due to past unfulfilled promises. Users discuss various treatments like minoxidil, finasteride, and microneedling, expressing doubt about the effectiveness of new methods.

A female experiencing hair loss while on testosterone replacement therapy is using oral Minoxidil, Spironolactone, and finasteride, but still losing hair. Suggestions include switching to dutasteride, using topical anti-androgens, and reducing Nizoral shampoo use to prevent scalp dryness.

The user has been using finasteride, minoxidil, dermarolling, and keto shampoo for hair regrowth, showing positive results after four months. Some users suggest adding tretinoin cream for better absorption, and there's a debate on whether finasteride should be taken at night.

Stem cell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.

Fit individuals often have full heads of hair, possibly due to lifestyle factors like exercise and diet, while those who are less fit tend to experience more hair loss. Some fit individuals may also use treatments like finasteride and minoxidil to maintain their hair.

Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.

Blocking DHT is not a cure for hair loss; instead, altering how scalp follicles respond to DHT might be more effective. Current treatments like topical finasteride and minoxidil are temporary solutions, and future approaches may involve gene therapy and bioengineering to change follicle behavior.

Blocking DHT is not a complete solution for hair loss; instead, altering the scalp's response to DHT may be more effective. Topical finasteride and minoxidil are current treatments, but future approaches may involve bioengineering, gene therapy, and inflammation control.

Switching from finasteride to dutasteride can cause hair shedding, with mixed results; some see improvement, others see worsening. Using both treatments together initially may help reduce shedding.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.